Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shaanxi Micot Technology
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Ischemic Stroke
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07205328 |
MT200605-II-C01 | P2 |
Recruiting |
Ischemic Stroke |
2026-05-01 |
2% |
2025-10-04 |
Primary Endpoints|Treatments |
NCT05948774 |
MT200605-I-C01 | P1 |
Completed |
Ischemic Stroke |
2024-01-22 |
22% |
2024-11-22 |
|
CTR20231741 |
CTR20231741 | P1 |
Completed |
Ischemic Stroke |
2023-12-28 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20253829 |
CTR20253829 | P2 |
Recruiting |
Ischemic Stroke |
None |
2025-10-28 |
Patient Enrollment|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|